Table 4 Baseline characteristics of COVID-19 patients and healthy controls included in the scRNA-seq of PBMC
HC | Group 1 | Group 2 | Group 3 | P value | ||||
|---|---|---|---|---|---|---|---|---|
(n = 4) | (n = 3) | (n = 4) | (n = 3) | (Group 3 vs Group 2) | (Groups 2 and 3 vs Group 1) | (Groups 2 and 3 vs HC) | (COVID-19 vs HC) | |
Age (year) | 28.5 ± 2.6 | 71.7 ± 5.8 | 64 ± 10.5 | 81 ± 2.2 | 0.064 | 0.96 | < 0.001 | < 0.001 |
Sex | ||||||||
Male/ female | 2 (50)/2 (50) | 3 (100)/ 0 | 3 (75)/ 1 (25) | 2 (66.7)/ 1 (33.3) | 0.81 | 0.3 | 0.48 | 0.26 |
Smoking | ||||||||
Never/ former/ current | 4 (100)/ 0/ 0 | 1 (33.3)/ 0/ 2 (66.7) | 2 (50) / 0/ 2 (50) | 1 (33.3)/ 0/ 1 (33.3) | 0.46 | 0.7 | 0.17 | 0.12 |
Hypertension | 0 | 2 (66.7) | 1 (25) | 2 (66.7) | 0.27 | 0.49 | 0.12 | 0.07 |
Diabetes mellitus | 0 | 0 | 1 (25) | 1 (33.3) | 0.81 | 0.3 | 0.24 | 0.33 |
Chronic kidney disease | 0 | 0 | 0 | 0 | - | - | - | - |
Days after onset | - | 7.7 ± 1.7 | 7.8 ± 2.0 | 8 ± 0.8 | 0.87 | 0.89 | - | - |
Days after corticosteroids | - | 1.3 ± 0.9 | 4 ± 1.6 | 2 ± 0.8 | 0.15 | 0.15 | - | - |